Defence Therapeutics Inc.

About Defence Therapeutics Inc.

Defence Therapeutics is a publicly traded Canadian pre-clinical biotechnology company focused on developing next-generation oncology solutions. Their mission is to shape the future of cancer treatment through smarter drug delivery using their proprietary Accum® platform, which enhances the potency of therapies, reduces toxicity, and lowers treatment costs.

Products & Services

Accum® Platform:A drug delivery technology that overcomes endosomal entrapment, ensuring therapeutic payloads reach the cell nucleus, boosting drug potency up to 60-fold, reducing toxicity, and lowering costs. It is applicable to ADCs, radiopharma, and potentially other biologics.

ADC Partnerships:Licensing Accum® to pharma and biotech companies to enhance the efficacy of existing Antibody-Drug Conjugates (ADCs), with proven in vivo results showing up to 60-fold potency increase.

Radiopharmaceutical Programs:Includes Actinium-225 collaboration with Canadian Nuclear Laboratories for precision radiotherapy targeting solid tumors, and a joint venture with Orano (50:50 partnership) to develop Radio-Immuno Conjugates (rADCs) combining ADC precision with radioactive payloads.

Specialties

Oncology Drug Delivery Antibody-Drug Conjugates (ADCs) Radiopharmaceuticals Radio-Immuno Conjugates (rADCs)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 2308625 MR: - FA: $2,308,625 FAN: 2308625	D: 2023-05-26 FD: 2023-05-26	-
2	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 5494375 MR: - FA: $5,494,375 FAN: 5494375	D: 2023-03-17 FD: 2023-03-17	1 investors
3	RT: Grant T: - FT: Grant	A: 1359851 MR: - FA: 1,359,851 FAN: 1359851	D: 2023-02-02 FD: 2023-02-02	2 investors

Warrant Exercise Latest

2023-05-26

$2.3M

Warrant Exercise 2023-03-17

$5.5M

Grant 2023-02-02

$1.4M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sébastien Plouffe

CEO and Director

D

Dr. Amie Phinney

Strategy & Business Advisor

M

Mr. Arnab De

CFO, Corporate Secretary

D

Dr. Maxime Parisotto

CSO

D

Dr. Svetlana Selivanova

Director

D

Dr. Sarkis Meterissian

Professor of Surgery and Oncology

View 5 more team members with Pro

Unlock Full Team Directory

Recent News